Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Vista Pharmaceuticals Ltd (524711)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524711 NSE: Pharmaceuticals & Drugs | Small Cap | Vista Pharmaceutical Share Price
₹5.75 0.15 (2.68%)
As on 11-Sep'26 16:59
Vista Pharmaceuticals Ltd (524711)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524711 NSE: Pharmaceuticals & Drugs | Small Cap | Vista Pharmaceutical Share Price
₹5.75 0.15 (2.68%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹35 Cr.
Current Price
₹5.8
52-Week Low / High
₹6 / 11
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.2
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-2.14%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
21.19%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹12.3 Cr.
Face Value
₹2
All Time Low / High
₹0.08 / 56.15
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Vista Pharmaceuticals Ltd a good quality company?
Vista Pharmaceuticals Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Vista Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Vista Pharmaceuticals Ltd vs industry peers?
Vista Pharmaceuticals Ltd revenue CAGR is %, compared to the industry median CAGR of 0.66%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Vista Pharmaceuticals Ltd?
Promoters hold 21.19% of the Vista Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Vista Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -12.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Vista Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.6% | 8.9% | 12.4% | 6.3% | -5.2% | -5.1% | -3.8% | -9.6% | -8.3% | -8.5% | - |
| Value Creation Index ⓘ | -0.3 | -0.4 | -0.1 | -0.6 | -1.4 | -1.4 | -1.3 | -1.7 | -1.6 | -1.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 15.4 | 24.2 | 28.9 | 31.1 | 22.8 | 1.3 | 0.4 | 1 | 10.3 | 10.1 | 4 |
| Sales YoY Gr. | - | 57.2% | 19.6% | 7.4% | -26.8% | -94.4% | -69.3% | 156.4% | 929% | -2.1% | - |
| Adj EPS ⓘ | 0.4 | 0.5 | 0.7 | 0 | -1.3 | -0.6 | -0.2 | -1.5 | -1 | -0.8 | -1.9 |
| YoY Gr. | - | 34.3% | 48.9% | -100% | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 4.5 | 6.3 | 9 | 11 | 9.8 | 8.9 | 9.6 | 8.1 | 7.6 | 7.4 | 5.8 |
| Adj Net Profit ⓘ | 0.9 | 1.3 | 2 | 0 | -3.8 | -2 | -0.9 | -5.6 | -4.5 | -4.6 | -12 |
| Cash Flow from Ops. ⓘ | -2.5 | 2.6 | -4.6 | 3.3 | 0.8 | -6.8 | -1 | -1.7 | -4.9 | -7 | - |
| Debt/CF from Ops. ⓘ | -3.2 | 4.4 | -2.4 | 3.4 | 19.3 | -1.6 | -12.6 | -5.8 | -1.6 | -1.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -4.6% | -15.1% | 195.6% | -2.1% | ||||
| Adj EPS ⓘ | -208.8% | NA | NA | NA | ||||
| BVPSⓘ | 5.7% | -5.4% | -8.5% | -2.4% | ||||
| Share Price | -12.5% | -9% | -31.5% | -41% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 8 | 9 | 8.4 | 0 | -11.6 | -6.4 | -2.5 | -15.4 | -11.6 | -10.8 | -29.1 |
| Op. Profit Mgn % ⓘ | 17.7 | 12.6 | 18.5 | 4 | -21.1 | -136.6 | -306.8 | -386.9 | -33.4 | -38.6 | -166.1 |
| Net Profit Mgn % ⓘ | 5.6 | 5.2 | 7 | 0 | -16.6 | -158.6 | -215.1 | -552.7 | -43.4 | -45.9 | -303 |
| Debt to Equity ⓘ | 0.7 | 0.7 | 0.4 | 0.3 | 0.5 | 0.3 | 0.4 | 0.3 | 0.2 | 0.2 | - |
| Working Cap Days ⓘ | 332 | 270 | 290 | 287 | 351 | 6,408 | 21,738 | 8,671 | 878 | 937 | 243 |
| Cash Conv. Cycle ⓘ | 95 | 52 | 59 | 153 | 249 | 3,977 | 13,580 | 6,495 | 313 | 213 | 28 |
Valuation of Vista Pharmaceutical - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Vista Pharmaceuticals Ltd FAQs
The current trading price of Vista Pharmaceutical on 11-Sep-2026 16:59 is ₹5.75.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Vista Pharmaceutical stood at ₹35.39 Cr
The latest P/E ratio of Vista Pharmaceutical as of 10-Sep-2026 is 0.00.
The latest P/B ratio of Vista Pharmaceutical as of 10-Sep-2026 is 1.00.
The 52-week high of Vista Pharmaceutical is ₹10.50 and the 52-week low is ₹5.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vista Pharmaceutical is ₹3.88 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vista Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Vista Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vista Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Vista Pharmaceuticals Ltd
Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America.
The Company was in process of setting up a 100% EOU for manufcacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum.
Vista, the largest division of Torrent Pharmaceuticals Ltd, offers a range of products mainly in the therapeutic areas of gastrointestinal, pain management and anti-infective, catering to common ailments. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
